Affimed Announces Annual General Meeting of Shareholders Mannheim, Germany

Affimed Announces Annual General Meeting of Shareholders

Mannheim, Germany, May 28, 2024 Affimed N.V. (Nasdaq: AFMD) ( Affimed , or the Company ), a

clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its 2024 Annual General Meeting of Shareholders (the Annual Meeting ) will be held on June 26, 2024

at 09:00 a.m. CET at the offices of De Brauw Blackstone Westbroek N.V., Burgerweeshuispad 201, 1076 GR Amsterdam, the Netherlands.

The notice and agenda

of the Annual Meeting are available on Affimed s website at https://www.affimed.com/investors/ under Annual General Meeting 2024 , as well as the SEC s website at www.sec.gov.

Affimed (Nasdaq: AFMD) is a

clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company s innate cell engagers (ICE ) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE are generated on the

Company s proprietary ROCK platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells. A number of ICE molecules are in clinical development, being studied as mono- or combination therapy. Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and

pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients lives. For more about the Company s people, pipeline and partners, please visit: www.affimed.com.

Director, Head of Investor Relations

Tel.: +1 (917) 436-8102